Since the first cases of COVID-19 were documented in Wuhan, China in 2019, the world has
witnessed a devastating global pandemic, with more than 238 million cases, nearly 5 million …

Although most mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) genome are expected to be either deleterious and swiftly purged or relatively …

In response to the emergence of SARS-CoV-2 variants of concern, the global scientific
community, through unprecedented effort, has sequenced and shared over 11 million …

Cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in
Manaus, Brazil, resurged in late 2020 despite previously high levels of infection. Genome …

The race to produce vaccines against severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) began when the first sequence was published, and this forms the basis for …

Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is
compounded in some areas by the higher transmission potential of the B. 1.1. 7 variant …

Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2.
However, ongoing surveillance has revealed the emergence of variants harboring mutations …

Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates …

The COVID-19 pandemic has had widespread effects across the globe, and its causative
agent, SARS-CoV-2, continues to spread. Effective interventions need to be developed to …

A novel variant of concern (VOC) named CAL. 20C (B. 1.427/B. 1.429), which was originally
detected in California, carries spike glycoprotein mutations S13I in the signal peptide …